Skip to content

The impact of Allopurinol in acute myocardial infarction

The impact of allopurinol versus placebo in patients with acute ST elevation myocardial infarction undergoing fibrinolytic therapy with streptokinase

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014062916229N3
Enrollment
146
Registered
2015-01-24
Start date
2014-05-31
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction. Acute transmural myocardial infarction of unspecified site

Interventions

Intervention 1: Intervention 1: patients will receive four oral Allopurinol 100mg tablets when arriving at the emergency department, followed by one 100mg tablet daily for 4 weeks. Allopurinol is a x
Treatment - Drugs
Intervention 1: patients will receive four oral Allopurinol 100mg tablets when arriving at the emergency department, followed by one 100mg tablet daily for 4 weeks. Allopurinol is a xanthine oxidase
Intervention 2: Placebo tablets are similar in appearance with Allopurinol tablets,which patients will receive four oral tablets when arriving at the emergency department, followed by one tablet daily

Sponsors

Vice chancellor for research,, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with first acute STEMI who are candidates for fibrinolytic therapy Exclusion criteria: Patients with firs acute STEMI who are candidates for Primary PCI, Patients with previous myocardial infarction or Primary valvular disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
ST resolution (in milimeter). Timepoint: On arriving at the emergency department (before the intervention) and 90 minute after streptokinase adminsteration(intervention) in emergency department. Method of measurement: ECG.

Secondary

MeasureTime frame
Cardiac biomarkers level. Timepoint: first 48 hour (arrival at the emergency department (before the intervention) and then daily(after the intervention)). Method of measurement: laboratory.;Heart failure. Timepoint: During hospitalization. Method of measurement: Physical examination and history and echocardiography.;Recurrent myocardial infarction. Timepoint: six month after intrvention (streptokinase). Method of measurement: Telephone follow-up and patients hospital records.;In hospital death. Timepoint: During hospitalization. Method of measurement: Physical examination.;Six month death. Timepoint: six month after intrvention (streptokinase). Method of measurement: Telephone follow-up and patients hospital records.;Re-hospitalization for acute decompensation of heart failure. Timepoint: six month after intrvention (streptokinase). Method of measurement: Telephone follow-up and patients hospital records.;Repeat revascularization. Timepoint: six month after intrvention (streptokinase). Method of measurement: Telephone follow-up and patients hospital records.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamad Ghaffari

Cardiovascular Research Center

ghafaris@gmail.com+98 41 3337 3819

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026